您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Ceralasertib(AZD-6738)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ceralasertib(AZD-6738)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ceralasertib(AZD-6738)图片
CAS NO:1352226-88-0
规格:≥98%
包装与价格:
包装价格(元)
1mg电议
2mg电议
5mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)412.51
FormulaC20H24N6O2S
CAS No.1352226-88-0
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 82 mg/mL (198.7 mM)
Water: <1 mg/mL
Ethanol: 41 mg/mL warmed (99.4 mM)
Solubility (In vivo)10% DMSO+40% propylene glycol+ddH2O: 10mg/mL
Synonyms

AZD6738; AZD-6738;AZD 6738

Chemical Name: (R)-imino(methyl)(1-(6-((R)-3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)cyclopropyl)-l6-sulfanone

InChi Key: OHUHVTCQTUDPIJ-JYCIKRDWSA-N

InChi Code: InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1

SMILES Code: C[S@@](=O)(C1(CC1)C2=NC(C3=C4C=CNC4=NC=C3)=NC(N5CCOC[C@H]5C)=C2)=N

实验参考方法
In Vitro

In vitro activity: AZD6738 is an orally available morpholino-pyrimidine-based, and selective inhibitor of the ATR (ataxia telangiectasia and rad3 related) kinase with IC50 of 1 nM. ATR is a serine/threonine protein kinase that is upregulated in various cancer cells, it plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress. AZD6738 has potential antineoplastic activity. Upon administration by oral route, AZD6738 selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1, which prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In an in vitro model capable of reproducing, over 70 hours after the initiation of the treatment with AZD6738, the γH2AX signal was sustained. Stalled replication forks may collapse the formation of DNA double stranded breaks and the activation of the ataxia telangiectasia mutated (ATM) kinase. As a single agent across cancer cell line panels, AZD6738 is active. In cell lines lacking ATM-pathway, the sensitivity of AZD6738 was enhanced.


Kinase Assay: AZD6738 is a potent inhibitor of ATR kinase activity with an IC50 of 0.001 μM against the isolated enzyme and 0.074 μM against ATR kinase-dependent CHK1 phosphorylation in cells.


Cell Assay: AZD6738 is dissolved in DMSO at 30 mM and diluted in DMSO to desired working concentrations. The final DMSO concentration in media for all conditions and controls is 0.1% for AZD6738 dose response experiments, 0.05% for AZD6738 + chemotherapy viability experiments, and 0.025% for all experiments involving 0.3 μM and 1.0 μM doses of AZD6738.

In VivoIn ATM-deficient but not ATM-proficient in vivo models, treatment with AZD6738 alone significantly inhibited the activity of tumors in equivalent, tolerated doses. Ionizing radiation (IR) is a DNA damaging inducing agent. When AZD6738 and IR were used together, regression or anti-tumor growth inhibitory activity was observed. In tumor tissue, AZD6738 is associated with a persistent γH2AX staining increase. In normal gut tissue or bone marrow, treatment with AZD6738 only transiently increased the γH2AX staining.
Animal modelMice
Formulation & DosageDissolved in DMSO at a concentration of 25 mg/mL or 50 mg/mL and diluted 1:5 in propylene glycol; Oral gavage at 25 mg/kg (H23) or 50 mg/kg (H460) for 14 consecutive days; the dosing volume is 10 mL/kg.
ReferencesLancet. 2015 Feb 26;385 Suppl 1:S58; Sci Rep. 2015 Aug 27;5:13545; Oncotarget. 2015 Dec 29;6(42):44289-305.